

3rd World Congress on Controversies in Neurology PRAGUE, CZECH REPUBLIC • OCTOBER 8-11, 2009

REGISTRATION

	Early Registration until July 15th, 2009	Late Registration from July 16th, 2009	On Site	
Participants	€ 490	€ 540	€ 590	
Nurses, students/trainees	€ 380	€ 430	€ 470	
Residents*	€ 320	€ 380	€ 420	
Accompanying Persons	€ 120			

* Non-tenured junior scientists

ACCOMMODATION

Official Congress Hotel	Category	Single room	Double room	Location to Congress Venue
Clarion Congress Hotel Standard Room	****	€ 149	€ 159	Congress Venue
Executive Room	****	€ 179	€ 189	Congress Venue

Rates quoted are per room, per night, including breakfast and VAT Additional hotels in different categories are available upon request

PRELIMINARY LIST OF SPONSORS































CONy Barcelona October 28-31, 2010



Headquarters and Administration: 53 Rothschild Boulevard, PO Box 68, Tel Aviv 61000, Israel Tel: +972-3-5666166 Fax: +972-3-5666177

Comtec Spain: Bailén, 95-97, pral. 1. a - 08009 Barcelona, Spain Tel: +34-93-2084445 Fax: +34-93-4579291

Comtec China: 175 Xiang Yang Road South, Shanghai 200031, China Tel: +86-21-54660460 Fax: +86-21-54660450

www.comtecmed.com/cony

The Academy for Clinical Debates & Controversies in Medicine announces:



3rd World Congress on **CONTROVERSIES IN NEUROLOGY**



PRAGUE, CZECH REPUBLIC • OCTOBER 8-11, 2009



A COMPREHENSIVE CONGRESS FULLY DEVOTED TO CLINICAL DEBATES AND CONTROVERSIAL ISSUES



This meeting is endorsed by the World Federation of Neurology. WFN members and all interested neurologists are encouraged to attend. The meeting is open to all neurologists regardless of citizenship.

The Academy for Clinical Debates & Controversies in Medicine announces:



3rd World Congress on

CONTROVERSIES IN NEUROLOGY

PRAGUE, CZECH REPUBLIC • OCTOBER 8-11, 2009

COMMITTEE



A.D. Korczyn, Israel CHAIRMAN



N. Bornstein, Israel Stroke Section Head



M. Sperling, USA Epilepsy Section Head



MS Section Head



A. Kupsch, Germany Movement Disorders Section Head



I. Steiner, Israel Infectious Diseases Section Head

LOCAL ADVISORY BOARD

I. Rektor, Chair

M. Bares M. Bojar

M. Brazdil E. Havrdova

J. Hort P. Kanovsky

P. Kalvach O. Keller

R. Kuba R. Mikulik I. Rektorova

R. Rusina E. Ruzicka

PRELIMINARY LIST OF CONFIRMED SPEAKERS

- A. Aguzzi, Switzerland
- D. Ames, Australia
- A. Antonini, Italy
- M. Bar. Czech Republic M. Bares, Czech Republic
- E. Beghi, Italy
- D. Bera. Germany
- K. Betterman, USA
- D. Blumenthal, USA
- M. Bojar, Czech Republic
- **H. Bolay**, Turkey
- D. Bondy, Czech Republic
- I. Bone, UK
- U. Bonnucelli, Italy
- M. Brazdil, Czech Republic M. Brodie, UK
- S. Chabardes, France J. Chapman, Israel
- A. Chaudhuri. UK G. Chrysant, USA
- C. Clarke, UK
- G. Comi, Italy
- C. Confavreux, France
- C. Cordonnier. France
- S.J. Czuczwar. Poland

- E. Ehler, Czech Republic
- P. Feldschreiber, UK
- M.D. Ferrari, The Netherlands G. Feuestein, USA
- E. Giacobini, Switzerland
- A. Guekht, Russia
- V. Hachinski. Canada
- A. Halliday, UK
- H.P. Hartung, Germany
- E. Havrdova, Czech Republic
- R. Hilker. Germany T. Ho. USA
- C. Hoschl, Czech Republic
- R. Itzhaki. UK
- M. Kapisyzi, Albania
- P. Kennedy, UK
- W. Kozubski, Poland
- R. Kuba, Czech Republic
- J. Kulisevsky, Spain
- J. Losy, Poland
- K. Marcus, Germany
- E. Martignoni, Italy
- A. Mauskap, USA
- N. Mathew, USA M. Memo. Italy

- H. Meyer, Germany A. Miller, Israel
 - R. Milo. Israel
 - I. Milonas. Greece
 - D. Mitsikostas, Greece
 - X. Montalban, Spain
 - D. Muresanu. Romania

 - M. Neufeld, Israel
 - P. Odin, Germany
 - F. Peng, Taiwan B. Popescu. Romania
 - N. Putzki. Switzerland
 - A. Rapoport, USA
 - O. Rascol, France R. Ravid, The Netherlands
 - H. Reichmann, Germany K. Rejdak, Poland
 - I. Rektor, Czech Republic
 - I. Rektorova, Czech Republic J. Roth, Czech Republic
 - D. Russell, Norway
 - P. Sandercock, UK
 - E. Ruzicka, Czech Republic A.V.H. Schapira, UK P. Schellinger. Germany

- L. Schneider, USA
- - J. Schoenen, Belgium
 - E. Shevel. South Africa

D. Schmidt. Germany

- H. Soares, USA
- T. Solomon, UK
- D. Spence. Canada M. Sperling, USA
- I. Steiner, Israel
- J. Streifler, Israel
- T. Tomson. Sweden
- J. Toole. USA J. Van Gijn, The Netherlands
- L. Vecsei, Hungary
- P. Vermersch, France S. Vukusic. France
- Z. Walker, UK
- U. Walter, Germany H. Wiendl, Germany
- I. Wirguin, Israel D. Woitalla, Germany
- J. Wojczal, Poland V. Zhang, China

PRELIMINARY LIST OF DEBATES

■ MULTIPLE SCLEROSIS

- Has Charcot taught us almost everything about MS?
- Antibodies are important for remyelination and recovery
- CSF examination is mandatory in every CIS case. regardless of MRI findings
- Escalation therapy vs. induction therapy
- Can we prevent MS with early life Vitamin D supplementation and EBV vaccination?
- Tysabri: Efficacy vs. side effects

■ STROKE

- Asymptomatic carotid stenosis: Surgery vs. stenting or just stick to medical therapy
- Be careful of CAA and microbleedings when giving antithrombosis treatment
- Does hyperbaric oxygen therapy have a role to play in acute stroke?
- IV tPA beyond 3 hours: Is it suitable for everyone?
- Statins should be given to every stroke patient for secondary stroke prevention
- Should mechanical embolectomy devices be used in routine clinical practice?

■ PARKINSON'S DISEASE

- Dementia discriminates PD from multiple system
- •The earlier the better: Dopaminergic treatment should be started immediately on diagnosis
- Should we start treatment with MAOB inhibitors or with dopamine agonists?
- What is the best treatment for advanced, fluctuating PD: Duodopa vs. apomorphine pump vs. DBS vs. IV
- Substantia nigra hyperecogenicity is a risk marker for
- Does PD have a prion-like pathogenesis?
- MCI in PD?
- Deep brain stimulation vs. ablative procedures for movement disorders

■ EPILEPSY

- Should prophylactic antiepileptic therapy be prescribed to patients with brain tumors?
- Ketogenic diet in adults: Does it work?
- Should valproate be prescribed to women of childbearing
- Is AED discontinuation in seizure-free patients dangerous?

■ HEADACHE

- •Temperature and barometric pressure are the most significant weather conditions for triggering migraine headache
- There is a need for developing GCRP antagonists for the treatment of migraine
- Triptans must be given early when the headache is mild for them to work well
- Are triptans safe to be used in basilar-type and hemiplegic migraine?
- · Patients with medication overuse headache should undergo withdrawal prior to initiating preventative
- medication • Is Migraine a neuronal disease or a vascular disease?

- **DEMENTIA** • Why so few new drugs on the market for AD therapy?
- Is the target the problem or the clinical trials? • Multifunctional drugs for AD therapy
- AD: Are we intervening too late?
- Brain reserve: Does it really exist?
- •Infectious agents: A cause of Alzheimer's disease? • Kinase inhibitors: Ubiquitous drugs or effective disease
- modifying therapy? • Is Alzheimer's disease a real disease?



many more ...

www.comtecmed.com/conv



